Oncology

Latest News

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

By Chris Ryan

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

By Maggie L. Shaw
David Nguyen, MD

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

By Mary Caffrey

July 23rd 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

By AJMC Contributor

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 25th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

AJMC Staff

Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.

November 8th 2017

ASCO: Alcohol Linked to Several Types of Cancer

Jaime Rosenberg

According to evidence gathered by the American Society of Clinical Oncology (ASCO), alcohol consumption is linked with an increased risk of cancer and can negatively impact cancer treatment.

November 7th 2017

Study to Explore Link Between Diabetes, Pancreatic Cancer

Mary Caffrey

Rising rates of diabetes and obesity have been cited in the fact that pancreatic cancer is expected to be the second-leading cause of cancer death by 2020.

November 7th 2017

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

Jaime Rosenberg

With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.

November 5th 2017

3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology

Alison Rodriguez

Recent advancements in technology, specifically in detection methods, have demonstrated significant improvement in how early patients are diagnosed with breast cancer and treated.

November 4th 2017

Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer

Laura Joszt, MA

In a pair of interviews, experts discuss neutropenia resulting from treatment of metastatic breast cancer with CDK4/6 inhibitors.

November 3rd 2017

This Week in Managed Care: November 3, 2017

AJMC Staff

This week, the top managed care news included the first day of open enrollment; data from CMS that indicate the progress accountable care organizations are making; and findings that most people with obesity aren't get screened for it or getting care.

November 3rd 2017

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer

Jaime Rosenberg

Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.

November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

November 1st 2017

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez

The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.

November 1st 2017

Evidence-Based OncologyTM Highlights Role of Pharmacist in Cancer Care

As cancer care becomes more expensive and complex, the role of the pharmacist is expanding, from managing the shift to greater use of oral therapies to navigating the revenue cycle, as explored in the new issue of Evidence-Based Oncology™, a publication of The American Journal of Managed Care.®

October 31st 2017

Educating Patients About Risk of Febrile Neutropenia Associated With Strong Chemotherapy

AJMC Staff

Strong chemotherapy may be part of the treatment plan for patients diagnosed with cancer, but it also comes with risks. A new campaign will empower patients with cancer to better understand and navigate risks such as febrile neutropenia that are associated with strong chemotherapy.

October 31st 2017

70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer

Jaime Rosenberg

Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.

October 30th 2017

Data Challenges Under the Oncology Care Model

Darcie Hurteau

An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.

October 30th 2017

Global Cancer Burden in Young Adults Differs From That in Other Age Groups

Jaime Rosenberg

A new study found that the global cancer burden in young adults differs from that in younger and older age groups and was more common in women.

October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez

Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.

October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez

October 28th 2017

Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC

Alison Rodriguez

October 27th 2017

Expanding Options for Individualized Treatment of Advanced NSCLC

Christina Mattina

James R. Jett, MD, gave an overview of the advances in diagnosis and treatment of non–small cell lung cancer (NSCLC) during a session at the National Association of Managed Care Physicians Fall Managed Care Forum 2017.

October 27th 2017

Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage

Alison Rodriguez

Many of survivors of childhood cancer who are now within the prime age for labor force participation are reluctant to make changes in their employment because of access to health insurance, and therefore, job lock is common among this population.

October 26th 2017

Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors

Kelly Davio

Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.

October 25th 2017

Stakeholders Weigh-in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD

Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.

October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD

Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.

October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.

October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.

October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD

Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.

October 24th 2017

Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.

October 24th 2017

Will 2-Sided Risk Be a Reality in OCM?

Kelly Davio

With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.

October 24th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD

Participants from 2 oncology community practices—an oncologist–administrator combination—shared their experience with implementing the Oncology Care Model (OCM) with attendees at the Community Oncology Alliance’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24, in Tysons Corner, Virginia.

...

64 65 66 67 68 69 70 71 72

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions